Mechanisms of antiepileptic drug resistance

Current Opinion in Neurology

Volumn 16, Issue 2, 2003, Pages 197-201

  Sisodiya, Sanjay M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drugs; Drug resistance; Multidrug resistance associated protein 1; P glycoprotein; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GLYCOPROTEIN P; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PHENOBARBITAL; PHENYTOIN; VALSPODAR;

ANTICONVULSANT THERAPY; BRAIN TISSUE; CELL POPULATION; CONCENTRATION RESPONSE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESISTANCE; EPILEPSY; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; NONHUMAN; PROTEIN BINDING; RAT; REVIEW;

ANIMALS; ANTICONVULSANTS; BRAIN; DRUG RESISTANCE; EPILEPSY; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN;

EID: 0037399407     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200304000-00013     Document Type: Review

References (42)

1. Kwan P, Brodie MJ, Early identification of refractory epilepsy. N Engl J Med 2000; 342:314-319.
2. Sander JW, Sillanpaa M. Natural history and prognosis. In: Engel J Jr, Pedley T, editors. Epilepsy. A comprehensive textbook. Philadelphia: Lippincott. Raven; 1998. pp. 69-86.
3. Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338:429-434.
4. MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48:833-841.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58. This is an excellent review of knowledge and experience to date of multidrug resistance mechanisms in cancer, providing further possible avenues for exploration in epilepsy.
6. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36:1-6.
7. Rundfeldt C, Honack D, Loscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology 1990; 29:845-851.
8. Loscher W, Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. J Pharmacol Exp Ther 1991; 258:483-489.
9. Loscher W. Animal models of drug-resistant epilepsy. Novartis Found Symp 2002; 243:149-159.
10. Ebert U, Loscher W. Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: influence of genetic factors. Epilepsy Res 1999; 33:217-226.
11. Cramer S, Ebert U, Loscher W. Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: comparison of inbred strains. Epilepsia 1998; 39:1046-1053.
12. Loscher W, Reissmuller E, Ebert U. Kindling alters the anticonvulsant efficacy of phenytoin in Wistar rats. Epilepsy Res 2000; 39:211-220.
13. Jeub M, Beck H, Siep E, et al. Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats. Neuropharmacology 2002; 42:107-116. This is a detailed study of possible physiological alterations in drug-resistant kindled rats.
14. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997; 40 (suppl):S3-S8.
15. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53:569-596. A comprehensive examination of transporter mechanisms operative in the central nervous system, and an excellent starting point for studies in epileptogenic brain tissue.
16. Bates SF, Chen C, Robey R, et al. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002; 243:83-96.
17. Sisodiya SM, Heffernan J, Squier MY. Over-expression of P-glycoprotein in malformations of cortical development. NeuroReport 1999; 10:3437-3441.
18. Lazarowski A, Sevlever G, Taratuto A, et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999; 21:731-734.
19. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56:3010-8020.
20. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9:363-382.
21. Seegers U, Potschka H, Loscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 2002; 43:675-684. A comprehensive immunohistochemistry study in this model, addressing a number of important technical and biological issues.
22. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999; 126:509-516.
23. Seegers U, Potschka H, Loscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 2002; 51:257-268. An illustration of the precision of experiments required to explore dynamic components of drug resistance phenomena.
24. Seegers U, Potschka H, Loscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002; 451:149-155. Data on failure of two particular enzyme-inducing drugs to upregulate P-lycoprotein expression in normal animal brain.
25. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002; 22:5833-5839. A comprehensive investigation of the effects of seizures and antiepileptic drugs on P-glycoprotein expression, with examination of the potential functional consequences in the same model.
26. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42:1501-1506. Excellent application of newer investigational methods to drug resistance in epilepsy, demonstrating overexpression at the mRNA level of a number of potentially relevant genes.
27. Seetharaman S, Barrand MA, Maskell L, Scheper RJ. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 1998; 70:1151-1159.
28. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125:22-31. A study of expression of P-glycoprotein and MRP1 in human epileptogenic brain tissue.
29. Shapiro AB, Fox K, Lee P, et al. Functional intracellular P-glycoprotein. Int J Cancer 1998; 76:857-864.
30. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-giycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49:311-318.
31. Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 2001; 500:365-372.
32. Potschka H, Loscher W. A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. NeuroReport 2002; 13:167-171. This comprehensive series of papers [32•, 33, 35, 36•, 39] studies the transport of antiepileptic drugs in vivo and the effects of transport inhibitors.
33. Potschka H, Loscher W. Muitidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. NeuroReport 2001; 12:2387-2389. See Ref. [32•]
34. Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and muitidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96:3900-3905.
35. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. NeuroReport 2001; 12:3557-3560. See Ref. [32•]
36. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327:173-176. See Ref. [32•]
37. Cox DS, Scott KR, Gao H, Eddington ND. Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther 2002; 302:1096-1104. The potential impact on antiepileptic drugs in development of P-glycoprotein-mediated transport is studied in this paper, with implications for drug development paradigms.
38. Cox DS, Scott KR, Gao H, et al. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J Pharm Sci 2001; 90:1540-1552.
39. Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001; 42:1231-1240. See Ref. [32•]
40. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
41. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36. A thorough study of the role of P-glycoprotein in a human disease state, with rigorous methodology and thoughtful consideration of complex results.
42. Stupp R, Bauer J, Pagani O, et al. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol 1998; 9:1233-1242.